Skip to main content

Table 1 The clinical characteristics of the study population

From: Neoadjuvant metformin added to conventional chemotherapy synergizes anti-proliferative effects in ovarian cancer

Characteristic No metformin use
n = 705 (96%)
Metformin use
n = 32 (4%)
p value
Diabetes rate% 19 (2.7%) 32 (100%) < 0.001 ***
Stagea%
 Early (I ~ II) 339 (51.1%) 16 (59.3%) 0.3168
 Late (III ~ IV) 324 (48.9%) 11 (40.7)  
Histologyb%
 Epithelial 542 (81.1) 24 (77.4) 0.5958
 Other typesc 126 (18.9) 7 (22.6)  
CA-125d# 1250 ± 273 767 ± 565 0.4109
Death rate% 239 (33.9%) 5 (15.6%) 0.0045 **
Overall survival 57.3 ± 4.2 69.7 ± 22.5 0.0338 *
  1. aFIGO stage: International Federation of Gynecology and Obstetrics, surgical staging of ovarian cancer; missing value not included in statistical test
  2. bMissing value not included in statistical test
  3. cincluding primary peritoneal serous carcinoma (PPSC)
  4. dbefore surgery, mean ± s.d. (U/ml)
  5. eoverall survival months, mean ± s.d.
  6. %calculated by Chi-square test
  7. #calculated by Student’s t-test
  8. §calculated by Kaplan-Meier Log-Rank test